Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5566700 | 0.80 | ALDH1A1 (0.65) | ALDH1A1KDM4ENPC1RAB9AMAPK1 | |
| SCHEMBL2759541 | 0.80 | ALDH1A1 (0.53) | KMT2AALDH1A1KDM4EGAANPC1 | |
| SCHEMBL13341898 | 0.78 | NPC1 (0.54) | ALDH1A1KDM4EGAANPC1RAB9A | |
| SCHEMBL859623 | 0.78 | ALDH1A1 (0.51) | KMT2AALDH1A1KDM4EGAANPC1 | |
| SCHEMBL859998 | 0.78 | KDM4E (0.65) | KMT2AALDH1A1KDM4EGAANPC1 | |
| SCHEMBL24348727 | 0.78 | DPP4 (0.63) | KMT2AALDH1A1KDM4EGAANPC1 | |
| SCHEMBL20138279 | 0.78 | KDM4E (0.51) | KMT2AALDH1A1KDM4EGAANPC1 | |
| SCHEMBL16156201 | 0.77 | KMT2A (0.58) | KMT2AALDH1A1KDM4EGAAMAPK1 | |
| SCHEMBL21995802 | 0.75 | KMT2A (0.47) | KMT2AALDH1A1KDM4EGAANPC1 | |
| SCHEMBL13220757 | 0.75 | KMT2A (0.51) | KMT2AALDH1A1KDM4EGAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2260020-B1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| EP-2628726-A1 | Hydroxamate-based inhibitors of deacetylases b | Novartis AG (CH) | 2013-08-21 | — | — | EP | disclosed |
| CN-102036955-B | Hydroxamate-based inhibitors of deacetylase B | NOVARTIS AG | 2013-03-27 | — | — | CN | disclosed |
| US-8349883-B2 | Hydroxamate-based inhibitors of deacetylases B | NOVARTIS AG (CH) | 2013-01-08 | — | — | US | disclosed |
| US-20110183964-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG (CH) | 2011-07-28 | — | — | US | disclosed |
| US-7943652-B2 | Hydroxamate-based inhibitors of deacetylases B | NOVARTIS AG (CH) | 2011-05-17 | — | — | US | disclosed |
| CN-102036955-A | Hydroxamate-based inhibitors of deacetylase B | NOVARTIS AG | 2011-04-27 | — | — | CN | disclosed |
| EP-2260020-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | Novartis AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| US-20090247547-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG | 2009-10-01 | — | — | US | disclosed |
| WO-2009118305-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247547-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | HDAC1, HDAC11, HDAC3 | KMT2A 103/4885ALDH1A1 238/4885KDM4E 305/4885 |
| US-20110183964-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | HDAC1, HDAC11, HDAC3 | KMT2A 103/4885ALDH1A1 238/4885KDM4E 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.